Roche Pharma China and Teva Announce Strategic Collaboration to Advance Standardized Lymphoma Care in China

2022Year4Month18Recently, Roche Pharma China announced a collaboration with Teva Pharmaceutical Industries Ltd. (hereinafter referred to as Teva), a well-known pharmaceutical company from Israel.“Teva”) to reach an innovative cooperation agreement, both parties will integrate their respective advantageous resources to further expand the original research of bendamustine hydrochloride——Cenda^®Accessible to patients in China. Through this collaboration, Roche Pharma China will further enrich its product pipeline in the field of hematological oncology, expand the full spectrum of lymphoma treatments, and continue to work with all parties to promote standardized lymphoma diagnosis and treatment in China.

Left:TevaGeneral Manager of Greater China RegionTheodor WeeMr.   Right: Ms. Bian Xin, President of Roche Pharma China

Innovative Collaboration Expands Original Research+Original Research Synergy

Cenda^®YesTevaThe company's independently developed original Bendamustine Hydrochloride,2018Approved in China in the year, isTevaThe company's original research product for treating patients during the treatment process with Rituximab or a Rituximab-containing regimen has been listed./Indolence of Disease Progression After TreatmentBCellular Non-Hodgkin Lymphoma (NHL）。

TevaGeneral Manager of Greater ChinaTheodor WeeMr. stated:“Cenda^®YesTevaThe First Drug Approved for Marketing in China，It is also one of the fundamental drugs for treating specific indolent lymphomas. We are very pleased to collaborate with Roche Pharma China this time, working together to benefit more Chinese lymphoma patients through the original bendamustine, reducing disease recurrence and improving quality of life. We also look forward to broader cooperation between both parties in the future.”

Roche andTevaThis collaboration will bring benefits to Cundar^®Combination use of Roche's original innovative drug Gazyva^®(Chinese Generic Name: Obinutuzumab and Verpozetuzumab (English generic name:Polatuzumab Vedotin)Lay a solid foundation, and in the future, it will better leverage original research.+The synergistic effect of the original research brings significant survival benefits to a wide range of Chinese lymphoma patients.

TevaVice President of Asia-Pacific Region, General ManagerMario MadeiraThe gentleman said:“TevaThe company's mission is to ensure that every patient worldwide receives the highest quality medications, and China is one of our most important markets globally. This strategic cooperation with Roche Pharma China, leveraging Roche's globally leading commercial layout and product innovation capabilities in the oncology field, will further enhanceTevaThe accessibility of the company's innovative drugs among Chinese patients, working together to create a healthy and bright future for Chinese patients.“

Business Model Innovation Boosts China's Lymphoma Prevention and Treatment Efforts

The pathology of hematological tumors is complex and diverse, and patients often face the risk of recurrence or even multiple recurrences. In developed countries, approximately70%Of5Compared to the annual survival rate, Chinese lymphoma patients5The survival rate after years remains only39%， To achieve“Healthy China2030”Proposed for cancer patients5Increase in annual survival rate15%The goal requires more innovative drugs and more standardized diagnosis and treatment.

As a leader in the field of hematology and oncology, Roche Pharma is committed to helping more lymphoma patients extend their disease-free survival time and reduce recurrence, improving their quality of life. Roche Pharma China is also continuously exploring innovative business models and external collaborations to bring better diagnosis and treatment experiences to lymphoma patients.

Ms. Bian Xin, President of Roche Pharma China, stated:”Currently, Roche is exploring a customer engagement business model centered on disease treatment areas, working with various partners to address each pain point encountered throughout the patient's overall treatment journey. This collaboration withTevaStrategic cooperation in pharmaceuticals is an important attempt for us to explore innovative collaboration models. In the future, Roche Pharma China will continue to accelerate the introduction of its innovative drugs into China. At the same time, we will actively and continuously seek innovative products that complement our pipeline, as well as innovative cooperation models in China. By working together with all parties, we aim to provide Chinese patients with more innovative and effective solutions, and jointly contribute to this cause.‘Healthy China2030’Grand Blueprint to Be Realized Soon 。”

Roche Pharma China andTevaRepresentatives from both pharmaceutical companies jointly launched an innovative strategic partnership

Innovative Drugs Bring More Hope to Lymphoma Patients

Roche Pharma China has long been committed to the field of lymphoma, and independently developed the world's first targeted drug.——MabThera^®(Rituximab) combined with chemotherapy regimens for up to20For many years, it has been the standard treatment regimen for non-Hodgkin's lymphoma globally. In recent years, Roche Pharma China has continuously developed innovative original drugs for lymphoma, such as Gazyva.^®(Obinutuzumab) and Verpozumab, etc.

Studies show that in the field of follicular lymphoma, the world's first glycosylatedⅡType AntiCD20 The monoclonal antibody Obinutuzumab, in combination with chemotherapy (CHOP/CVP/Bendamustine) regimen, compared to previous first-line standard treatment regimens, can reduce the risk of recurrence in newly diagnosed patients and significantly prolong patientPFS. For patients with rituximab-refractory indolent non-Hodgkin lymphoma,GBThe regimen compared to bendamustine monotherapy (B) can significantly extend the patient'sPFSRecently2Times (GB 25.8Month vs B 14.1months), and significantly extend overall survival (OS）（GB 88.3Month vs B 65.6Month). Obinutuzumab was2021Year8Launched in the same year and entered the medical insurance system in China, with2022The nationwide implementation of medical insurance in China,GBThe combination regimen will benefit more patients.

In diffuse largeBCellular Lymphoma (DLBCL) field, according to global multicenter clinicalIIPhase ExperimentGO29365Research shows that targetedCD79bAntibody-drug conjugate Polivy in combination with bendamustine and rituximab (referred to as Pola-BR) regimen compared to bendamustine combined with rituximab (BR), the optimal complete remission rate significantly increased (CR：57.5% vs 20%), more than doubled progression-free survival (medianPFS 9.2Months vs 3.7Months), Overall survival extended more than twice (medianOS：12.4Months vs 4.7months), and reduce58%The risk of death." The experimental results also became the basis for Polivy's approval in Europe and the United States for relapsed or refractory diffuse largeBImportant Basis for Cell Lymphoma.